IMMUNOMEDICS INC Form 8-K June 30, 2010

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 30, 2010

Immunomedics, Inc. (Exact Name of Registrant as Specified in Charter)

Delaware 000-12104 61-1009366

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

300 American Road, Morris Plains, New Jersey 07950 (Address of Principal Executive Offices) (Zip Code)

(973) 605-8200 (Registrant's telephone number, including area code)

Not applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pu	arsuant to Rule 425 und	der the Securities Act (17 CFR 230.425).
---------------------------	-------------------------	--------------------------	------------------

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
--

- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events.

Effective June 30, 2010, Immunomedics, Inc. (the "Company") terminated the services of American Stock Transfer and Trust Company as the Company's transfer agent and registrar for shares of the Company's common stock \$0.01 par value per share (the "Common Stock"), and appointed StockTrans, Inc. to serve as the Company's transfer agent and registrar for shares of the Company's Common Stock. Contact information for the Company's transfer agent is as follows:

StockTrans, Inc. 44 West Lancaster Avenue Ardmore, PA 19003 800-733-1121

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.

By: /s/ Cynthia L. Sullivan Name: Cynthia L. Sullivan

Title: President and Chief Executive Officer

Dated: June 30, 2010